Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

We claim: 
     
         1 . A method for treatment of chronic lymphocytic leukemia, acute lymphoblastic leukemia or non-Hodgkin's lymphoma in a patient, said method comprising administering to the patient an antibody specific for CD19 wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and a Bruton's tyrosine kinase (BTK) inhibitor. 
     
     
         2 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell. 
     
     
         3 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is follicular lymphoma. 
     
     
         4 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma. 
     
     
         5 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue. 
     
     
         6 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma. 
     
     
         7 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma. 
     
     
         8 . The method according to  claim 1 , wherein the non-Hodgkin's lymphoma is mantle cell lymphoma. 
     
     
         9 . The method according to  claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered separately. 
     
     
         10 . The method according to  claim 1 , wherein the Bruton's tyrosine kinase (BTK) inhibitor of said combination is administered prior to administration of the antibody specific for CD19. 
     
     
         11 . The method according to  claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered simultaneously. 
     
     
         12 . The method according to  claim 1 , wherein the antibody specific for CD19 and the Bruton's tyrosine kinase (BTK) inhibitor of said combination are administered at a time where both drugs are active in the patient at the same time.